Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.
- Author:
Joshua F HEIBER
1
;
Xiang-Xi XU
;
Glen N BARBER
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antineoplastic Agents; pharmacology; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Oncolytic Virotherapy; methods; Ovarian Neoplasms; pathology; therapy; virology; Vesicular stomatitis Indiana virus; physiology; Virus Replication
- From:Chinese Journal of Cancer 2011;30(12):805-814
- CountryChina
- Language:English
- Abstract: In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.
